CSL Limited (CSL.AX)
| Previous close | 296.90 |
| Open | 299.90 |
| Bid | 297.55 x 13700 |
| Ask | 297.56 x 21700 |
| Day's range | 296.20 - 301.14 |
| 52-week range | 242.00 - 320.42 |
| Volume | 481,663 |
| Avg. volume | 639,078 |
| Market cap | 135.589B |
| Beta (5Y monthly) | 0.14 |
| PE ratio (TTM) | 42.34 |
| EPS (TTM) | 7.03 |
| Earnings date | 17 Aug 2021 |
| Forward dividend & yield | 2.94 (0.99%) |
| Ex-dividend date | 02 Sept 2021 |
| 1y target est | 312.57 |
- PR Newswire
Seqirus Receives FDA Approval of its Cell-Based Quadrivalent Influenza Vaccine, Expanding the Age Indication to Include Children as Young as Six Months
Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX: CSL), today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the company's cell-based quadrivalent influenza vaccine, for an expanded age indication for children as young as six months old.4 With this approval, FLUCELVAX QUADRIVALENT, the first and only cell-based influenza vaccine in the U.S., is now indicated for everyone eligible to receive
- PR Newswire
The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) Efficacy in Children and Adolescents ≥2 to <18 Years of Age
Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX:CSL), today announced that The New England Journal of Medicine has published absolute efficacy data on the company's cell-based quadrivalent influenza vaccine (QIVc) from a randomized controlled trial (RCT) which met its primary endpoint.1 The study indicates that the seasonal influenza vaccine was effective and produced a sufficient immune response against influenza in children and adolescents ≥2 to <18 years o
- PR Newswire
Seqirus Awarded U.S. Government Contract to Develop Two Pandemic Influenza Vaccines
Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), has selected Seqirus to develop two influenza A(H2Nx) virus vaccine candidates for assessment in a Phase 1 clinical study with the goal of helping to safeguard communiti
